Mutational Signatures (v3.5 - November 2025)

CN25 · GRCh37 · COSMIC v103

Mutational profile

Copy number signatures are defined by a 48 context copy number classification scheme. The scheme incorporates loss-of-heterozygosity status, total copy number state, and segment length to categorise segments from allele-specific copy number profiles.

The scheme corresponds to three heterozygosity states:

  1. heterozygous segments with copy number of [A>0, B>0] (numbers reflect the counts for major allele A and minor allele B)
  2. segments with LOH with copy number of [A>0, B=0]
  3. segments with homozygous deletions [A=0, B=0]

Segments are further subclassified into 6 classes based on the sum of major and minor allele (total copy number) and chosen for biological relevance:

  1. total copy number (TCN)=0 (homozygous deletion)
  2. TCN=1 (deletion leading to LOH)
  3. TCN=2 (wild type, including copy-neutral LOH)
  4. TCN=3 or 4 (minor gain)
  5. TCN=5 to 8 (moderate gain)
  6. TCN>=9 (high-level amplification).

Each of the heterozygous and LOH total copy number states are then organised into five classes based on the size of their segments: 0 – 100kb, 100kb – 1Mb, 1Mb – 10Mb, 10Mb – 40Mb, and >40Mb (the largest category for homozygous deletions was restricted to >1Mb) in order to capture focal, large scale, and chromosomal-scale copy number changes. This gives a total of 48 copy number context to categorise segments into (3x homozygous deletion categories, 5*5=25x LOH categories, 4*5=20 heterozygous categories).

Proposed aetiology

CN25 is associated with MSH6 inactivation and dMMR.

Comments

CN25 is composed of <1Mb loss of heterozygosity (LOH) deletions (similar to CN9 involving LoH >1Mb), which is indicative of chromothripsis. However, unlike other chromothripsis-associated CN signatures, CN4 and CN8, CN25 is composed of low total copy number states with single copy LOH and diploid heterozygous states.

Acceptance criteria

Supporting evidence for mutational signature validity

Validated evidence for real signature
Unclear evidence for real signature
Evidence for artefact signature
Background Identification study First included in COSMIC
Everall et al. 2026 Nature Genetics v3.4
Identification NGS technique Different variant callers Multiple sequencing centres
WGS Yes Yes
Technical validation Validated in orthogonal techniques Replicated in additional studies Extended context enrichment
Yes No -
Proposed aetiology Mutational process Support
MMR deficiency Statistical association
Experimental validation Experimental study Species
- -

Summary of the technical and experimental evidence available in the scientific literature regarding the validation of the mutational signature.

Tissue distribution

Feature of CNS, connective tissue, and prostate cancers.

Please note: While you do not need to log in to access this module, use of the data is still subject to the COSMIC Terms and Conditions which can be found here. By continuing on this site, you agree to these terms.